Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 3/20 | 0.60 |
| ▸ | JAK3 | P52333 | 3/20 | 0.60 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | TYK2 | P29597 | 2/20 | 0.58 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.58 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.57 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.57 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.57 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | STK16 | O75716 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28153587 | 0.90 | PLK4 (0.56) | PLK4JAK2JAK3CSF1RTYK2 | |
| SCHEMBL29370869 | 0.81 | CDK1 (0.63) | PLK4JAK2JAK3CSF1RTYK2 | |
| SCHEMBL270735 | 0.80 | PLK4 (0.60) | PLK4JAK2JAK3CSF1RTYK2 | |
| SCHEMBL13901171 | 0.80 | TBK1 (0.66) | PLK4JAK2JAK3CSF1RTYK2 | |
| SCHEMBL12423160 | 0.80 | JAK2 (0.61) | PLK4JAK2JAK3CSF1RTYK2 | |
| SCHEMBL4035821 | 0.80 | FLT3 (0.66) | PLK4JAK2JAK3CSF1RTYK2 | |
| SCHEMBL4874932 | 0.79 | JAK2 (0.56) | PLK4JAK2JAK3CSF1RTYK2 | |
| SCHEMBL13946389 | 0.79 | NCF1 (0.65) | PLK4CSF1RTYK2TBK1KDR | |
| SCHEMBL4367879 | 0.79 | NCF1 (0.60) | PLK4JAK2JAK3KDRCDK1 | |
| SCHEMBL4162420 | 0.78 | CDK2 (0.64) | PLK4JAK2JAK3CSF1RTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | PLK4 1378/4885JAK2 910/4885JAK3 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.